Gülnur ÖZAKŞİT, Elif Gül EYİ YAPAR, Yunus YILDIZ, Hasan ENERGİN, Emre ÖZGÜ, Bekir Serdar ÜNLÜ

Insulin resistance, metabolic status and relation between metabolic parameters in polycystic ovary syndrome patients

Amaç: Polikistik over sendromu(PCOS) tanısı konulmuş bireylerde klinik, metabolik ve hormonal parametreler, insülin direnci araştırması ve birbiri ile ilişkilerini incelemekti. Yöntem ve Gereçler: Ağustos 2010- ağustos 2011 tarihleri arasında Zekai Tahir Burak Kadın Sağlığı ve Hastalıkları Hastanesi İnfertilite ve Gençlik Merkezi Polikliniklerine adet düzensizliği, tüylenmede artış, obezite şikâyetleri ile başvuran toplam 81 hastada da yapıldı. Tüm hastalarda serum açlık insülin ve glukoz, 75 gr. oral glukoz tolerans test (OGTT), düşük dansiteli lipoprotein (LDL), trigliserid (TG), yüksek dansiteli lipoprotein (HDL), 17-hidroksiprogesteron, dehidroepiandrostenedion, androstenedion, total ve serbest testosteron, tiroid stimulan hormon (TSH) seviyeleri araştırıldı. Vücut kitle indeksi (VKI) ve Homeostasis Model Assessment of İnsulin Resistance (HOMA-IR) skorları hesaplandı. Bulgular: VKI değerlendirmesinde VKI>25 (n=32 %39,5) olan hastalarda HOMA-lR skoru, açlık insülin seviyesi ve 2.saat 75 gr OGTT değeri, VKI25 olan gruba göre anlamlı derecede yüksek idi (p

Polikistik over hastalarında insulin direnci, metabolik durum ve metabolik parametreler arasındaki ilişki

Aim: to investigate the hormonal status, insulin resistance, clinical and metabolic parameters and their correlation in polycystic ovary syndrome (PCOS) patients. Material And Methods: The study was performed on a total of 81 patients with menstrual irregularity, hirsutism and obesity who were admitted to Zekai Tahir Burak Women s Health Educational and Research Hospital infertility and adolescent outpatient clinics between August 2010- August 2011. The serum levels of fasting insulin and glucose, 75 g oral glucose tolerance test (OGTT), low density lipoproteins (LDL), triglyseride (TG), high density lipoproteins (HDL), 17-hydroxyprogesterone, dehydroepiandrostenedione, androstenedione, total and free testosterone, thyroid stimulan hormon (TSH) were investigated, and body mass index (BMI), homeostasis model assessment of insulin resistance (HOMA-IR) scores were calculated for all participants. Results : On Body Mass Index (BMI) match tests; serum levels of fasting glucose, fasting insulin and 2. hour 75 gr OGTT results were significantly higher in patients with BMI>25 (n=32 %39,5) (p25 (n=49 %60,5) serum levels of triglyseride were significantly higher than patients with BMI

PDF

___

1.Farah, L., et al., Prevalence of polycystic ovary syndrome in women seeking treatment from community electrologists. Alabama Professional Electrology Association Study Group. J Reprod Med, 1999. 44(10): p. 870-4.
2.Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod, 2004. 19(1): p. 41-7.
3.Azziz, R., et al., Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab, 2006. 91(11): p. 4237-45.
4.Barbieri, R.L. and M.D. Hornstein, Hyperinsulinemia and ovarian hyperandrogenism. Cause and effect. Endocrinol Metab Clin North Am, 1988. 17(4): p. 685-703.
5.Arlt, W., R.J. Auchus, and W.L. Miller, Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3beta -hydroxysteroid dehydrogenase. J Biol Chem, 2001. 276(20): p. 16767-71.
6.Dunaif, A., et al., Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes, 1989. 38(9): p. 1165-74.
7.Beamer, B.A., et al., Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes, 1998. 47(11): p. 1806-8.
8.Crave, J.C., et al., Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab, 1995. 80(7): p. 2057-62.
9.De Leo, V., A. la Marca, and F. Petraglia, Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev, 2003. 24(5): p. 633-67.
10.Poretsky, L., et al., Distribution and characterization of insulin and insulin-like growth factor I receptors in normal human ovary. J Clin Endocrinol Metab, 1985. 61(4): p. 728-34.
11.Poretsky, L., et al., The insulin-related ovarian regulatory system in health and disease. Endocr Rev, 1999. 20(4): p. 535-82.
12.Azziz, R., Androgen excess is the key element in polycystic ovary syndrome. Fertil Steril, 2003. 80(2): p. 252-4.
13.Talbott, E., et al., Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a casecontrol study. J Clin Epidemiol, 1998. 51(5): p. 415-22.
14.Speroff L, Fritz MA. Clinical Gynecologic Endocrinology and Infertility. Seventh edition. Lippincott Williams and Wilkins Philadelphia 2005.p.502-503,471,488-490
15.Balen, A.H., et al., Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod, 1995. 10(8): p. 2107-11.
16.Wild, R.A., Obesity, lipids, cardiovascular risk, and androgen excess. Am J Med, 1995. 98(1A): p. 27S-32S.
17.Conway, G.S., et al., Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol (Oxf), 1992. 37(2): p. 119-25.
18.Aherne SA. polycystic ovary syndrome.Nursing Standart 18(26):40- 44, 2004
19.Legro, R.S., Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev, 2003. 24(3): p. 302-12.
20.Kauffman, R.P., et al., Polycystic ovarian syndrome and insulin resistance in white and Mexican American women: a comparison of two distinct populations. Am J Obstet Gynecol, 2002. 187(5): p. 1362-9.
21.Gennarelli, G., et al., Prediction models for insulin resistance in the polycystic ovary syndrome. Hum Reprod, 2000. 15(10): p. 2098-102.
22.Im JA, Kim SH, Lee JW, Shim JY, Lee HR, Lee DC. Association betweenhypoadiponectinemia and cardiovascular risk factors in nonobese healthy adults.Metabolism. 2006 Nov;55(11):1546-50.
23.Panidis, D., et al., Association of the T45G polymorphism in exon 2 of the adiponectin gene with polycystic ovary syndrome: role of Delta4- androstenedione. Hum Reprod, 2004. 19(8): p. 1728-33.
24.Stefan, N., et al., Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes, 2002. 51(6): p. 1884-8.
25.Indhavivadhana, S., et al., Prevalence of metabolic syndrome in reproductive- aged polycystic ovary syndrome Thai women. J Med Assoc Thai, 2010. 93(6): p. 653-60.
26.Cosar, E., et al., Body fat composition and distribution in women with polycystic ovary syndrome. Gynecol Endocrinol, 2008. 24(8): p. 428-32.
27.Yucel, A., V. Noyan, and N. Sagsoz, The association of serum androgens and insulin resistance with fat distribution in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol, 2006. 126(1): p. 81-6.
28.Rogez, G., et al., Layered hydroxide hybrid nanostructures: a route to multifunctionality. Chem Soc Rev, 2011. 40(2): p. 1031-58.